NVCR Quote, Financials, Valuation and Earnings

Tivic Health Systems has a net margin of -22.14% compared to NovoCure's net margin of -2145.71%. NovoCure's return on equity of -45.51% beat Tivic Health Systems's return on equity of -192.41%.

NovoCure has a consensus price target of $32.57, signalling upside risk potential of 70.44%. On the other hand Tivic Health Systems has an analysts' consensus of -- which suggests that it could fall by --. Given that NovoCure has higher upside potential than Tivic Health Systems, analysts believe NovoCure is more attractive than Tivic Health Systems.

NovoCure has a beta of 0.739, which suggesting that the stock is 26.1% less volatile than S&P 500. In comparison Tivic Health Systems has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

NovoCure has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tivic Health Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovoCure pays -- of its earnings as a dividend. Tivic Health Systems pays out -- of its earnings as a dividend.

NovoCure quarterly revenues are $155M, which are larger than Tivic Health Systems quarterly revenues of $70K. NovoCure's net income of -$34.3M is lower than Tivic Health Systems's net income of -$1.5M. Notably, NovoCure's price-to-earnings ratio is -- while Tivic Health Systems's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovoCure is 3.34x versus 3.51x for Tivic Health Systems. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -22.14% compared to NovoCure's net margin of -2201.34%. NovoCure's return on equity of -45.51% beat VolitionRX's return on equity of --.

NovoCure has a consensus price target of $32.57, signalling upside risk potential of 70.44%. On the other hand VolitionRX has an analysts' consensus of $2.93 which suggests that it could grow by 482.11%. Given that VolitionRX has higher upside potential than NovoCure, analysts believe VolitionRX is more attractive than NovoCure.

NovoCure has a beta of 0.739, which suggesting that the stock is 26.1% less volatile than S&P 500. In comparison VolitionRX has a beta of 1.072, suggesting its more volatile than the S&P 500 by 7.247%.

NovoCure has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovoCure pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

NovoCure quarterly revenues are $155M, which are larger than VolitionRX quarterly revenues of $246.4K. NovoCure's net income of -$34.3M is lower than VolitionRX's net income of -$5.4M. Notably, NovoCure's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovoCure is 3.34x versus 34.67x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of -22.14% compared to NovoCure's net margin of -2828.67%. NovoCure's return on equity of -45.51% beat Catheter Precision's return on equity of -137.84%.

NovoCure has a consensus price target of $32.57, signalling upside risk potential of 70.44%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 981.67%. Given that Catheter Precision has higher upside potential than NovoCure, analysts believe Catheter Precision is more attractive than NovoCure.

NovoCure has a beta of 0.739, which suggesting that the stock is 26.1% less volatile than S&P 500. In comparison Catheter Precision has a beta of -0.850, suggesting its less volatile than the S&P 500 by 184.968%.

NovoCure has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovoCure pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

NovoCure quarterly revenues are $155M, which are larger than Catheter Precision quarterly revenues of $143K. NovoCure's net income of -$34.3M is lower than Catheter Precision's net income of -$4M. Notably, NovoCure's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovoCure is 3.34x versus 2.12x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -22.14% compared to NovoCure's net margin of 0.18%. NovoCure's return on equity of -45.51% beat Xtant Medical Holdings's return on equity of -26.62%.

NovoCure has a consensus price target of $32.57, signalling upside risk potential of 70.44%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 165.03%. Given that Xtant Medical Holdings has higher upside potential than NovoCure, analysts believe Xtant Medical Holdings is more attractive than NovoCure.

NovoCure has a beta of 0.739, which suggesting that the stock is 26.1% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.181, suggesting its less volatile than the S&P 500 by 118.091%.

NovoCure has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovoCure pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

NovoCure quarterly revenues are $155M, which are larger than Xtant Medical Holdings quarterly revenues of $32.9M. NovoCure's net income of -$34.3M is lower than Xtant Medical Holdings's net income of $58K. Notably, NovoCure's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovoCure is 3.34x versus 0.74x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.